Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-502-2311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees92
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) released its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.06. The biopharmaceutical company earned $5.05 million during the quarter, compared to analysts' expectations of $2.61 million. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
6 Wall Street analysts have issued 12-month target prices for Stemline Therapeutics' shares. Their forecasts range from $17.00 to $35.00. On average, they expect Stemline Therapeutics' share price to reach $25.20 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.
What is the consensus analysts' recommendation for Stemline Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.
What are Wall Street analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (3/5/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)
Has Stemline Therapeutics been receiving favorable news coverage?
Media stories about STML stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include The Medicines (MDCO), Myokardia (MYOK), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Uniqure (QURE), Insmed (INSM), Ligand Pharmaceuticals (LGND), Portola Pharmaceuticals (PTLA), Endocyte (ECYT), Xencor (XNCR), AnaptysBio (ANAB), Allakos (ALLK), Akcea Therapeutics (AKCA), Arrowhead Pharmaceuticals (ARWR) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Stemline Therapeutics own?
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
- Mr. Robert Francomano, Sr. VP & Global Head of Commercial
- Mr. John A. Salvagno, Sr. VP of Quality & Operations
Who are Stemline Therapeutics' major shareholders?
Stemline Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (6.90%), BlackRock Inc. (6.21%), Goldman Sachs Group Inc. (3.12%), The Manufacturers Life Insurance Company (2.79%), FMR LLC (2.10%) and Schonfeld Strategic Advisors LLC (1.79%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Which institutional investors are selling Stemline Therapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Citigroup Inc., Morgan Stanley, Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Which institutional investors are buying Stemline Therapeutics stock?
STML stock was acquired by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, BlackRock Inc., Man Group plc, C WorldWide Group Holding A S, Pier Capital LLC and Fosun International Ltd. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $14.30.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $624.77 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.
What is Stemline Therapeutics' official website?
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
